Business Intelligence on Biologic and Small Molecule Drugs
Figure 1 – Overview of process to repurpose existing drugs for cancer indications
Figure 1. Overview of process to repurpose existing drugs for cancer indications. Symbolic (i.e., hourglass) representation of a proposed timeline for new chemical entities (dashed hourglass outline) and repurposed drugs (solid, colored hourglass) from hypothesis generation and project funding, to product commercialization and patient benefit. Labels within funding, discovery, approval, and commercialization stages denote requirements/strategies for successful movement through each. The center of the hourglass denotes the “bottleneck” between approval and commercialization, and highlights the facilitated approval of drugs for rare oncological indications (purple dashed oval) compared with drugs repurposed for other indications (gray dashed oval).
Figure 1. Overview of process to repurpose existing drugs for cancer indications. Symbolic (i.e., hourglass) representation of a proposed timeline for new chemical entities (dashed hourglass outline) and repurposed drugs (solid, colored hourglass) from hypothesis generation and project funding, to product commercialization and patient benefit. Labels within funding, discovery, approval, and commercialization stages denote requirements/strategies for successful movement through each. The center of the hourglass denotes the “bottleneck” between approval and commercialization, and highlights the facilitated approval of drugs for rare oncological indications (purple dashed oval) compared with drugs repurposed for other indications (gray dashed oval).